TCT-3 A randomized comparison of drug-eluting vs. bare metal stenting in patients with non-ST elevation myocardial infarction. Results of the ELISA-3 angiographic substudy  by Remkes, Wouter et al.
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMAcute Coronary Syndromes (non STEMI)
Washington Convention Center, Lower Level, Hall A
Saturday, September 13, 2014, 5:00 PM–7:00 PM
Abstract nos: 1-8
TCT-1
Left atrial dysfunction assessed with strain is related to long-term adverse events
in an elderly patients after acute coronary syndrome with percutaneous coronary
intervention
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Background: Although larger left atrial (LA) volume is known as a powerful pre-
dictor of adverse events in patients after acute myocardial infarction (MI), elderly
patients have larger LA volume in a general way. This study aimed to evaluate the
relationship between LA volume, dysfunction using strain and long-term adverse
events in an elderly patients after acute coronary syndrome (ACS).
Methods: Consecutive elderly patients admitted with ACS treated with percutaneous
coronary intervention (PCI) were evaluated. LA volume and strain (longitudinal
global strain) were quantiﬁed within 48 h of admission. The clinical endpoint was a
composite of all-cause mortality, MI, stroke and hospitalization for heart failure (HF).
Results: 225 patients (mean age, 73.811 years, 51.1% males) were followed up for
3013 months. During follow-up, 44 adverse events (19.5%) developed ; 19 all-cause
deaths, 4 MIs, 7 strokes and 14 hospitalizations for HF. After adjusting clinical and
echocardiographic parameters, LA volume (adjusted HR 1.02, 95% CI 0.96-1.09, p ¼
0.034) and LA strain (adjusted HR 1.20, 95% CI 1.01-1.41, p ¼ 0.015) independently
predicted the occurrence of the composite endpoint (Table 1). In addition, LA strain
increased the predictive power to LA volume (p ¼ 0.04) for the prediction of adverse
events in an elderly patients after ACS.Table 1. Predictors of composite endpoint (all-cause mortality, MI, stroke and
hospitalization for HF) by multivariate Cox regression analysis
Variable Adjusted HR 95% CI p Value
LA longitudinal global strain (%) 1.20 1.01-1.41 0.015
LA volume (ml/m2) 1.02 0.96-1.09 0.034
LV ejection fraction (%) 1.01 0.94-1.09 0.688
ST elevation MI 3.01 0.27-33.13 0.368
E/E’ ratio 0.93 0.78-1.10 0.373
MI, myocardial infarction; HF, heart failure; HR, hazard ratio; CI, conﬁdence interval; LA, left
atrial; LV, left ventricular.Conclusions: LA dysfunction assessed with LA strain provides additional value to LA
volume for the prediction of adverse events in an elderly patients after ACS with PCI.
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Background: The ECG is central to the triage of patients with suspected acute cor-
onary syndromes (ACS) but its accuracy in detecting coronary artery occlusion is
limited. We sought to determine the incidence, distribution and outcomes of totally
occluded culprit arteries among non-ST-segment elevation ACS (NSTEACS) patients.
Methods: The ACUITY trial was a randomized trial that enrolled 13,819 patients pre-
senting with NSTEACS undergoing early invasive strategy. We excluded patients with
multi-vessel disease and prior CABG. We compared baseline features and outcomes in
patients with an occluded (baseline TIMI 0-1) vs patent (TIMI 2-3 ﬂow) culprit vessel.
Results: Of 2,406 ACUITY patients who met study criteria, 328 (13.6%) had TIMI 0-
1 ﬂow in the culprit artery, and the RCA and LCX were more frequently occluded
than the LAD (Figure). Patients with totally occluded culprit arteries were less likely
to have hypertension and hyperlipidemia, and were more likely to have baseline ST
deviation >1mm (36.9% vs 22.8%, p < 0.0001) and biomarker elevation (82.6% vs
55.1% p < 0.0001). 1-year outcomes, including death (10.4% vs. 10.5%, p¼0.89) and
myocardial infarction (7.9% vs. 9.1%, p¼0.44), did not differ signiﬁcantly betweenJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Acpatients with vs. without occluded culprit arteries. Results were consistent after
sensitivity analysis for patients with biomarker elevation.Conclusions: The culprit artery is occluded in w1/7 patients presenting with
NSTEACS and single-vessel disease. The presence of total occlusion was not asso-
ciated with an incremental hazard of mortality or MI at 1 year.
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Background: Many studies have evaluated the safety and efﬁcacy of drug-eluting
stents (DES) in patients with ST elevation myocardial infarction (STEMI), however,
randomized data in patients with Non-STEMI are scarce. In addition, few studies have
compared the newer, second generation DES stents versus a cobalt chromium bare
metal stent (BMS).
Methods: Patients with Non-STEMI included in the Early or Late Intervention in
unStable Angina 3 (ELISA-3) trial or patients with Non-STEMI who did not meet the
criteria for inclusion in ELISA-3 (RELI (¼Registration ELISA) patients) during the
study period who underwent percutaneous coronary intervention (PCI) were ran-
domized to an everolimus coated DES (Xience V) or a cobalt chromium BMS
(Vision). Primary endpoint of the ELISA-3 angiographic substudy was the incidence
of restenosis, deﬁned as a diameter stenosis of more than 50% at 9 month follow-up
angiography, as assessed by an independent core-lab. The incidence of MACE and
stent thrombosis at 2 years follow-up was the key secondary and safety endpoint
respectively in the combined ELISA-3 and RELI patients.
Results: During the study period, 474 patients (178 ELISA-3, 296 RELI) were ran-
domized (234 DES and 240 BMS). Baseline clinical and angiographic characteristics
were comparable between the groups. Nine-month follow-up angiography was per-
formed in 119 (67%) of the ELISA-3 patients. Restenosis occurred in 1.9% in the DES
group vs. 16.7% in the BMS group (RR 0.11, 95% CI 0.02-0.84, p¼ 0.007). The
incidence of MACE (12.3% (DES) vs. 15.8% (BMS), p¼0.323) or stent thrombosis
(1.6% (DES) vs. 3.6% (BMS), p¼0.339) in the combined study group did not differ
signiﬁcantly between the groups at 2 years follow-up.
Conclusions: The use of an everolimus eluting second generation drug-eluting stent in
patients with Non-STEMI is safe and decreases restenosis as compared to a cobalt
chromium bare-metal stent.
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Background: We assess clinical factors and decisions beyond the Global Registry of
Acute Coronary Events (GRACE) risk score that inﬂuence timing of revascularizationute Coronary Syndromes (non STEMI) B1
